Monitoring systemic immune responses to checkpoint inhibition in breast cancer reveals host responses and mechanisms of resistance
These findings provide insight into resistance mechanisms and suggest the potential for minimally invasive strategies (sampling of systemic immune cells from peripheral blood) to identify patients likely to respond to ICI. This approach may help inform de-escalation strategies to mitigate therapeutic toxicities and limit unnecessary treatments.
Authors
- Ann Hanna (ORCID: https://orcid.org/0000-0003-2734-6426)
- Melinda E. Sanders (ORCID: https://orcid.org/0000-0001-7227-1764)
- Xiaopeng Sun (ORCID: https://orcid.org/0009-0009-5219-8964)
- Paula I. González-Ericsson (ORCID: https://orcid.org/0000-0002-6292-6963)
- Violeta Sánchez (ORCID: https://orcid.org/0000-0001-6639-9024)
- Quanhu Sheng (ORCID: https://orcid.org/0000-0001-8951-9295)
- Susan R. Opalenik (ORCID: https://orcid.org/0000-0001-9965-1986)
- Abigail Toren
- James R. Marshall (ORCID: https://orcid.org/0000-0001-8956-5945)
- Elizabeth C. Wescott (ORCID: https://orcid.org/0000-0003-3340-213X)
- Brandie C. Taylor (ORCID: https://orcid.org/0000-0002-4862-4678)
- Justin Micah Balko (ORCID: https://orcid.org/0000-0002-4263-5974)
- Carly M. Fielder
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012606
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Vanderbilt University
- National Institutes of Health
- National Cancer Institute